Organisation paid for research Program year 2024 Source: CMS Open Payments

Clarkston Skin Research PC

Neither a doctor nor a teaching hospital

Research payments

$294,898

81 payments

Through program year 2024, Clarkston Skin Research PC is reported as receiving $294,898 in research payments, across 81 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $700 1
2023 Research $24,781 6
2021 Research $57,672 14
2020 Research $92,993 35
2019 Research $118,751 25

Breakdown

Who paid Research payments · program years 2019–2024
  1. AbbVie, Inc. $201,986 58 payments
  2. Sanofi US Services Inc. $49,196 8 payments
  3. Pfizer Inc. $34,866 14 payments
  4. Dermira, Inc. $8,850 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. M16-047 $103,089 23 payments
  2. A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable $33,140 6 payments
  3. M15-999 $30,995 11 payments
  4. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $24,781 6 payments
  5. A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 to 18 Years of Age With Moderatetosevere Atopic Dermatitis $19,434 6 payments
  6. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $15,409 7 payments
  7. M16-046 $14,639 6 payments
  8. An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $11,732 6 payments
  9. A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapie $9,306 1 payment
  10. A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis $9,123 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record